SAMD9L and systemic sclerosis: The presence of SAMD9L and IRAK1 variants in patients with SSc-ILD (χ2 = 4.9–7.8, p < 0.02) supports their potential involvement in fibrogenic signalling and interferon-mediated inflammation.